204 related articles for article (PubMed ID: 37793862)
1. [Novel therapeutic agents for hemolytic anemia].
Nishimura JI
Rinsho Ketsueki; 2023; 64(9):884-891. PubMed ID: 37793862
[TBL] [Abstract][Full Text] [Related]
2. [Novel anti-complement therapeutics for hemolytic anemia].
Nishimura JI
Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
[TBL] [Abstract][Full Text] [Related]
3. Molecular pharmacology in complement-mediated hemolytic disorders.
Bortolotti M; Barcellini W; Fattizzo B
Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
[TBL] [Abstract][Full Text] [Related]
4. Novel insights into the treatment of complement-mediated hemolytic anemias.
Berentsen S; Hill A; Hill QA; Tvedt THA; Michel M
Ther Adv Hematol; 2019; 10():2040620719873321. PubMed ID: 31523413
[TBL] [Abstract][Full Text] [Related]
5. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
6. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Jäger U; D'Sa S; Schörgenhofer C; Bartko J; Derhaschnig U; Sillaber C; Jilma-Stohlawetz P; Fillitz M; Schenk T; Patou G; Panicker S; Parry GC; Gilbert JC; Jilma B
Blood; 2019 Feb; 133(9):893-901. PubMed ID: 30559259
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress in paroxysmal nocturnal hemoglobinuria and other conditions of complement-mediated hemolysis.
Fibach E; Dana M
Free Radic Biol Med; 2015 Nov; 88(Pt A):63-9. PubMed ID: 25937178
[TBL] [Abstract][Full Text] [Related]
9. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
10. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Risitano AM
Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
12. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
13. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
[TBL] [Abstract][Full Text] [Related]
15. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.
Peffault de Latour R; Hosokawa K; Risitano AM
Semin Hematol; 2022 Jan; 59(1):38-46. PubMed ID: 35491057
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
17. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
Gavriilaki E; de Latour RP; Risitano AM
Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
[TBL] [Abstract][Full Text] [Related]
18. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
DeZern AE; Brodsky RA
Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
[TBL] [Abstract][Full Text] [Related]
19. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Risitano AM; Frieri C; Urciuoli E; Marano L
Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036
[TBL] [Abstract][Full Text] [Related]
20. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]